Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

AstraZeneca Crestor study

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

AstraZeneca will evaluate whether long-term use of Crestor (rosuvastatin) will decrease major cardiovascular events in patients with normal cholesterol levels and elevated C-reactive protein in the 15,000-patient JUPITER (Justification for the Use of statins in Primary prevention: an Intervention Trial Evaluating Rosuvastatin) study. The firm hopes to demonstrate that Crestor can prevent cardiovascular events in patients with elevated CRP levels; the patient population does not qualify for treatment under current cholesterol guidelines. The randomized, double-blind, placebo-controlled study is part of AstraZeneca's 80,000-patient GALAXY program. Enrollment is also beginning in the METEOR study in carotid atherosclerosis and the ASTEROID study in coronary atherosclerosis. Data from the first two completed GALAXY studies, STELLAR and MERCURY I, evaluating comparative efficacy versus other statins is being presented April 2 at the American College of Cardiology Congres
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS002206

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel